McCormick & Co. Inc. Stock Rises Friday, Still Underperforms Market

Oramed Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

ORMP Oramed Pharmaceuticals Inc

GOTU Gaotu Techedu Inc

SGDVV Safe & Green Development Corp

GLBZ Glen Burnie Bancorp

PHAR Pharming Group NV

CARD Max Auto Industry -3X Inverse Leveraged ETN

HIW Highwoods Properties Inc

HFRO Highland Opportunities and Income Fund

HDV iShares Core High Dividend ETF

HDELY Heidelberg Materials AG

Health Care : Pharmaceuticals | Small Cap Blend

Company profile

Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.

McCormick & Co. Inc. Stock Rises Friday, Still Underperforms Market

5:10 pm ET April 28, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of McCormick & Co. Inc. (MKC) inched 0.51% higher to $87.85 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.83% to 4,169.48 and the Dow Jones Industrial Average rising 0.80% to 34,098.16.

This was the stock's second consecutive day of gains.

McCormick & Co. Inc. closed $15.51 short of its 52-week high ($103.36), which the company reached on April 29th.

Trading volume (2.2 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled April 28, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 28, 2023 17:10 ET (21:10 GMT)

Premarket

Change Since Close

Market Hours

McCormick & Co. Inc. Stock Rises Friday, Still Underperforms Market